Aileron Therapeutics, Inc. (ALRN): Price and Financial Metrics

Aileron Therapeutics, Inc. (ALRN): $0.41

-0.01 (-1.95%)

POWR Rating

Component Grades













Add ALRN to Watchlist
Sign Up

Industry: Biotech



in industry

ALRN Stock Price Chart Interactive Chart >

Price chart for ALRN

ALRN Price/Volume Stats

Current price $0.41 52-week high $1.34
Prev. close $0.42 52-week low $0.32
Day low $0.40 Volume 138,900
Day high $0.44 Avg. volume 318,404
50-day MA $0.43 Dividend yield N/A
200-day MA $0.60 Market Cap 37.42M

Aileron Therapeutics, Inc. (ALRN) Company Bio

Aileron Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of therapeutics called stapled peptides, which represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. The company's lead product candidate ALRN-6924 is being evaluated in multiple clinical trials. The company was founded in 2005 and is based in Cambridge, Massachusetts.

ALRN Latest News Stream

Event/Time News Detail
Loading, please wait...

ALRN Latest Social Stream

Loading social stream, please wait...

View Full ALRN Social Stream

Latest ALRN News From Around the Web

Below are the latest news stories about Aileron Therapeutics Inc that investors may wish to consider to help them evaluate ALRN as an investment opportunity.

Morgan Jess S & Co Inc Buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Sells ...

Investment company Morgan Jess S & Co Inc (Current Portfolio) buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Microsoft Corp, Vanguard Total International Stock, sells Amgen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Morgan Jess S & Co Inc.

Yahoo | January 27, 2022

Aileron Therapeutics (ALRN) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | January 11, 2022

H.C. Wainwright Thinks Aileron Therapeutics’ Stock is Going to Recover

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Aileron Therapeutics (ALRN – Research Report), with a price target of $2.00. The company's shares closed last Wednesday at $0.59, close to its 52-week low of $0.53. According to, White is a 4-star analyst with an average return of 8.9% and a 36.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics. Currently, the analyst consensus on Aileron Therapeutics is a Moderate Buy with an average price target of $3.50.

Christine Brown on TipRanks | January 5, 2022

Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones

Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial on track for interim results in 2Q22 and topline results in 4Q22 Dosed first 10 patients in NSCLC trial; on track to conduct blinded safety evaluation on these patients after one cycle in 1Q22 In 2021, Aileron was issued 7 new international patents, including

Yahoo | January 5, 2022

Aileron Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will provide a company overview and business update at the H.C. Wainwright BIOCONNECT Conference, which will be held virtually January 10th – 12th and the Emerging Growth Conference, which will be held

Yahoo | January 4, 2022

Read More 'ALRN' Stories Here

ALRN Price Returns

1-mo N/A
3-mo -19.98%
6-mo -27.16%
1-year -69.17%
3-year -43.06%
5-year -96.32%
YTD -27.16%
2021 -45.88%
2020 81.50%
2019 -31.79%
2018 -92.03%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5242 seconds.